Cargando…

Who Treats Cancer?

Detalles Bibliográficos
Autor principal:	Woll, Penella J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal College of Physicians of London 1987
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379413/ https://www.ncbi.nlm.nih.gov/pubmed/3820158

Ejemplares similares

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update
por: Young, Robin J., et al.
Publicado: (2017)

Immune responses following intrapleural administration of oncolytic SEPREHVIR in patients with malignant pleural mesothelioma
por: Learmonth, Kirsty, et al.
Publicado: (2015)

Relative Hypocalcaemia and Muscle Cramps in Patients Receiving Imatinib for Gastrointestinal Stromal Tumour
por: M. Zekri, Jamal, et al.
Publicado: (2006)

Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells
por: Zhu, Yong Ming, et al.
Publicado: (2008)

A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma
por: McTiernan, Anne, et al.
Publicado: (2006)

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
por: Manegold, Christian, et al.
Publicado: (2012)

Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines
por: Salawu, Abdulazeez, et al.
Publicado: (2016)

The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()
por: Lee, Siow Ming, et al.
Publicado: (2019)

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
por: Shah, Manisha H., et al.
Publicado: (2016)

Neuropeptide growth factors and cancer.
por: Woll, P. J.
Publicado: (1991)

Intention to treat--who should use ITT?
por: Lewis, J. A., et al.
Publicado: (1993)

Pulmonary hypertension, how to diagnose and who to treat?
por: Roos-Hesselink, J. W., et al.
Publicado: (2011)

Ascorbic Acid Alleviates Water Stress in Young Peach Trees and Improves Their Performance after Rewatering
por: Penella, Consuelo, et al.
Publicado: (2017)

Powering Autonomous Sensors: An Integral Approach with Focus on Solar and RF Energy Harvesting
por: Penella-López, María Teresa, et al.
Publicado: (2011)

Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2016)

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
por: Lee, Siow Ming, et al.
Publicado: (2012)

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
por: Woll, Penella J., et al.
Publicado: (2023)

SLAP TEARS IN THE PEDIATRIC PATIENT: WHO IS TREATING THEM AND WHERE?
por: Agatstein, Lauren, et al.
Publicado: (2019)

Treating early psychosis: who, what, and when?
por: Cornblatt, Barbara A., et al.
Publicado: (2005)

Aphasia Recovery: When, How and Who to Treat?
por: Doogan, Catherine, et al.
Publicado: (2018)

Hypothyroidism in the Elderly: Who Should Be Treated and How?
por: Calsolaro, Valeria, et al.
Publicado: (2018)

Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab
por: Cui, Wei, et al.
Publicado: (2017)

The pandemic and the ethical dilemma of limited resources: Who to treat?
por: Palazzani, Laura
Publicado: (2020)

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
por: Ferry, David, et al.
Publicado: (2017)

Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer.
por: Woll, P. J., et al.
Publicado: (1988)

1616. Clinical Characteristics of Children with Congenital Cytomegalovirus Diagnosed Retrospectively by Dried Blood Spot
por: Del Valle Penella, Ana, et al.
Publicado: (2023)

Utility of Dried Blood Spots for the Diagnosis of Congenital Cytomegaloviruses within the First 21 Days of Life in a Single Center
por: Del Valle Penella, Ana, et al.
Publicado: (2023)

Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis
por: Liu, Tsai-Ling, et al.
Publicado: (2018)

The Question of Treating the Poor Who Can Not Pay the Physician
Publicado: (1897)

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
por: Leighl, N B, et al.
Publicado: (2011)

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
por: Faivre-Finn, Corinne, et al.
Publicado: (2017)

The experiences of physiotherapists treating people with dementia who fracture their hip
por: Hall, AJ, et al.
Publicado: (2017)

Consideraciones a la hipersensibilidad al aroma de melocotón como excipiente
por: Reyes Balaguer, Javier, et al.
Publicado: (2015)

Superior temporal activation as a function of linguistic knowledge: Insights from deaf native signers who speechread
por: Capek, Cheryl M., et al.
Publicado: (2010)

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events
por: Logan, Jessica M., et al.
Publicado: (2021)

Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer
por: Coulson, J M, et al.
Publicado: (1999)

Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy?
por: Wang, Jin, et al.
Publicado: (2019)

The risk of developing cardiovascular disease is increased for patients with prostate cancer who are pharmaceutically treated for depression
por: Wollersheim, Barbara M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_95mcp6aif55apfpvk2lilkkklg